SCHEMBL3103235

SCHEMBL3103235

CCN(C(=O)C(Cc1ccc(OC)c([N+](=O)[O-])c1)C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.52
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LDHA P00338 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
GAA P10253 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 3/20 0.43
GPR55 Q9Y2T6 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3079152 0.92 LDHA (0.46) ALDH1A1MEN1KMT2ALDHASMN1; SMN2
SCHEMBL3097574 0.86 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3079461 0.86 LDHA (0.64) ALDH1A1LDHATSHRPKMALOX15
SCHEMBL3089238 0.84 ALDH1A1 (0.43) ALDH1A1MEN1KMT2APKMGAA
SCHEMBL3089116 0.83 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3089113 0.83 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3096395 0.80 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3103823 0.80 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3078912 0.79 HPGD (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL3085743 0.76 RAPGEF3 (0.42) ALDH1A1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 ALDH1A1 617/4885MEN1 2509/4885KMT2A 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.